Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus Beta-Glucan in CLL/SLL
NCT00290407Phase 2Terminated
- Sponsor
- University of Louisville
- Start
- Mar 2006
- Primary completion
- Jan 2010
- Modality
- Microbiome Therapeutics, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and beta-D-glucan in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Louisville. Primary endpoint: CT Scan to Measure Clinical Effect (Response). Started Mar 2006; status: terminated.
02
Drugs
rituximabbeta-D-glucan
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00290407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290407.